• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • How Doku became key player for treble-chasing Man City

  • The Eurovision Song Contest reaches its grand final with pop and protests

  • Trump says Islamic State group leader was killed in a joint US-Nigerian mission

  • Would FA Cup win paper over the cracks for Chelsea?

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube